Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04132570
Other study ID # CCSURA001265
Secondary ID CCSURA0012655034
Status Completed
Phase Phase 4
First received
Last updated
Start date October 22, 2019
Est. completion date January 22, 2020

Study information

Verified date January 2021
Source Johnson & Johnson Consumer and Personal Products Worldwide
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to assess the effectiveness of intranasal budesonide aqueous spray 256 microgram (mcg)/day for treatment of rhinitis symptoms during times of high airborne pollution.


Recruitment information / eligibility

Status Completed
Enrollment 206
Est. completion date January 22, 2020
Est. primary completion date January 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Self-reported rhinitis symptoms triggered or worsened by airborne pollution, with agreement by physician at screening visit - Participant must have moderate to severe rhinitis symptoms as defined by a 24-hour reflective total nasal symptom score (rTNSS) of at least 5 (maximum 9), based on three individual nasal symptom scores (nasal obstruction, secretion/runny nose, itching/sneezing) at the time of the screening visit, including at least one individual symptom score of 3 for nasal obstruction and/or secretion/runny nose - Regularly have outdoor exposure during a normal week in the winter season, including greater than or equal to (>=) 1 hour on most days. Outdoor exposure may include commuting activities (such as walking/bicycle/auto/bus/city metro train travel), outdoor work, exercise, shopping, or other outdoor activities - A woman of childbearing potential must have a negative urine pregnancy test (beta human chorionic gonadotropin [beta hCG]) at screening and agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 30 days after the last administration of study agent - Male participants who are not surgically sterilized and are heterosexually active with a woman of childbearing potential, must agree to use a barrier method of contraception (example condom with spermicidal foam/gel/film/cream/suppository) and to not donate sperm during the study and for 30 days after last receiving study agent. Note that barrier methods must also be used in all male subjects sexually active with pregnant partners for at least 30 days after last study agent administration - Participants can understand the questionnaires and are able to complete the questionnaires in the format provided - Reside in the same city as the study site that they will be visiting Exclusion Criteria: - History of hypersensitivity to budesonide or any ingredients in the formulation - Upper respiratory infection within 2 weeks of screening visit - Current symptoms consistent with diagnosis of common cold, influenza, or other respiratory infection according to physician evaluation - Using of N-95 masks days during with high airborne pollution - Presence of nasal polyps or deviated septum as confirmed by nasal endoscopy - History of nasal surgery - Presence of chronic or active rhinosinusitis or sinusitis - Systemic, intranasal or topical corticosteroid use within 1 month, intranasal or systemic decongestants within 3 days, antihistamine use within 1 week, intranasal cromolyn within 2 weeks, leukotriene use within 1 month, or immunotherapy within 2 years of screening visit - Asthma, with the exception of mild intermittent asthma not requiring medication - Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (example compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Budesonide
Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\- 3 Days.
Other:
Placebo
Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\- 3 Days.

Locations

Country Name City State
China The No.2 Hospital of Baoding Baoding Hebei
China Beijing Tongren Hospital, Cmu Beijing Beijing
China Cangzhou Center Hospital Cangzhou Hebei
China Shandong provincial hospital Jinan Shandong
China The Second Hospital to Hebei Medical University Shijiazhuang Hebei
China The No.2 People'S Hospital Og Weifang Weifang Shandong

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change from Baseline in 24-hour Reflective Total Nasal Symptom Score (rTNSS) Mean change from baseline in 24-hour reflective total nasal symptom score (rTNSS) calculated as the sum of the participant-assessed 24-hour reflective severity ratings for three individual nasal symptom scores (nasal obstruction, secretion/runny nose, itching/sneezing) averaged over the first 10-day treatment period. Baseline value will be a single 24-hour rTNSS recorded on the no-treatment evening following the baseline visit. The individual nasal symptom scores will be recorded at home by participants in their diary on a four point scale (from 0=none to 3=severe). The sum of the individual scores will form the 24-hour rTNSS. Baseline up to 10 days (24 hours each day)
Secondary Subject Global Impression of Change (SGIC) at the Final Efficacy Assessment Participant will rate Global Impression of Change at Final Efficacy Assessment on a 5-point scale from 0 (symptoms were aggravated) to 4 (total control over symptoms). An increase in score indicates the improvement in condition. Day 10 (+/-3)
Secondary Mean Change from Baseline in Individual Nasal Symptoms Scores (NSS) Mean Change from Baseline in individual NSS for nasal obstruction, secretion/runny nose, and itching/sneezing averaged over the first 10-day treatment period will be reported using 4-point scale from 0=None, 1=Mild, 2=Moderate, or 3=Severe. Baseline to 10 days (24 hours each day)
Secondary Mean Change from Baseline in 24-hour Reflective Individual non-Nasal Symptoms Score (Cough and Post-Nasal Drip) Mean Change from Baseline in 24-hour reflective Individual non-Nasal Symptoms Score for cough and post-nasal drip averaged over the first 10-day treatment period, using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe condition. Baseline to 10 days (24 hours each day)
Secondary Number of Participants With Adverse Events (AEs) as a Measure of Safety An AE is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Up to Day 10 +/- 3 days or up to 30 days after the last day of the study treatment period (Day 10)
See also
  Status Clinical Trial Phase
Completed NCT02340130 - Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma Phase 2
Completed NCT02360072 - Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
Completed NCT01118312 - Study of Asthma and Nasal Steroids Phase 4
Completed NCT00762567 - Phenylephrine Pediatric Pharmacokinetic Study Phase 1
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Completed NCT00279916 - Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays Phase 3
Completed NCT00524836 - Efficacy and Safety of Levocetirizine Versus Loratadine for the Treatment of Perennial Allergic Rhinitis Phase 3
Completed NCT00963573 - Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428) Phase 4
Completed NCT00521131 - Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites Phase 4
Completed NCT02784262 - Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis Phase 2
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3
Terminated NCT02630472 - Topical Irrigation Therapy for CRS Phase 1/Phase 2
Completed NCT02279706 - Korean Linguistic Adaptation of Rhinitis Controlled Assessment Test N/A
Completed NCT01971086 - Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary N/A
Completed NCT01771120 - Control and Burden of Asthma and Rhinitis N/A
Completed NCT01469234 - A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712) Phase 4
Withdrawn NCT01177852 - Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis Phase 3
Completed NCT02879929 - Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction N/A
Completed NCT00724698 - Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed NCT02272101 - Rhinitis in the Elderly: The Role of Vitamin D Phase 3

External Links